Clinical trials: Disorder, Mood
Depressive Disorder, Major
Zelquistinel in the Treatment of Major Depressive Disorder
The purpose of this study is to evaluate the efficacy at 1 day post initial oral dose of zelquistinel (AGN-241751) compared with placebo in participants with Major Depressive Disorder (MDD).
- Trial name
- AGN-241751 (NCT03586427)
- Testing
- AGN-241751
- Where
- 25 sites in United States
- Volunteers
- 251 people
- Sponsor
- Syndeio Biosciences, Inc
Treatment Resistant Depression
Tianeptine for Treatment Resistant Depression
The studies will be conducted in parallel at two sites: the the Mood and Anxiety Disorders Program at the Icahn School of Medicine at Mount Sinai (MSSM), and Stanford Depression Research Clinic at Stanford University School of…
- Trial name
- NCT04249596
- Testing
- Tianeptine Sodium
- Where
- 3 sites in United States
- Volunteers
- 38 people
- Sponsor
- Jonathan A. Javitch, MD, PhD
Depressive Disorder
Memantine Augmentation of Antidepressants
This study is evaluating the efficacy and safety of the drug memantine (trade name NAMENDA) as an augmentation agent for the treatment of depression in people who are not fully responding to antidepressant medications.
- Trial name
- NCT00344682
- Testing
- memantine
- Where
- United States
- Volunteers
- 31 people
- Sponsor
- University of Massachusetts, Worcester
Mood Disorder, Disruptive Behavior Disorders
Oxytocin on Irritability/Emotional Dysregulation of Disruptive Behavior and Mood Disorders
Irritability and emotional dysregulation are recognized as serious aspects of psychopathology seen in in pediatric psychiatric patients.
- Trial name
- NCT02824627
- Testing
- Oxytocin
- Where
- United States
- Volunteers
- 58 people
- Sponsor
- University of Nebraska
Bipolar Depression
Lumateperone Monotherapy for the Treatment of Bipolar Depression Conducted Globally
The study will evaluate the efficacy and safety of ITI-007 in a randomized, double-blind, parallel-group, placebo-controlled, multi-center study in patients diagnosed with Bipolar I or Bipolar II disorder having a major…
- Trial name
- NCT03249376
- Testing
- Lumateperone
- Where
- 47 sites in United States, Bulgaria and 4 more
- Volunteers
- 381 people
- Sponsor
- Intra-Cellular Therapies, Inc.
Depression, Bipolar Depression
Low Field Magnetic Stimulation in Mood Disorders Using the LFMS Device
This study is designed to test whether low-field magnetic stimulation (LFMS) can relieve some of the symptoms of depression in bipolar disorder or major depression.
- Conditions
- Depression, Bipolar Depression, Major Depressive Disorder
- Trial name
- LFMS (NCT00578383)
- Testing
- Low Field Magnetic Stimulation Device
- Where
- United States
- Volunteers
- 107 people
- Sponsor
- Mclean Hospital
Bipolar Disorder
Lithium and Divalproex for the Treatment of Comorbid Rapid Cycling Bipolar Disorder and Substance Abuse Disorder
This study will determine the efficacy and safety of combination therapy with divalproex and lithium for treating mania in people with rapid cycling bipolar disorder and a substance abuse disorder.
- Trial name
- NCT00194129
- Testing
- Lithium, Divalproex
- Where
- United States
- Volunteers
- 31 people
- Sponsor
- University Hospitals Cleveland Medical Center
Major Depressive Disorder
Effect of Amygdala Neurofeedback on Depressive Symptoms and Processing Biases
The purpose of this study is to determine whether upregulating the left amygdala during positive autobiographical memory recall via real time functional magnetic resonance imaging neurofeedback will lead to an improvement in…
- Trial name
- NCT02079610
- Testing
- real-time fMRI neurofeedback: Amygdala, real-time fMRI neurofeedback: HIPS
- Where
- United States
- Volunteers
- 36 people
- Sponsor
- Laureate Institute for Brain Research, Inc.
Depressive Disorder
MDD POC Study GSK372475 Subjects Depressive Disease
To evaluate the efficacy, safety and tolerability of GSK372475 compared with placebo in the treatment of outpatients subjects with major depressive disorder to exhibit decreased pleasure, interest and energy.
- Trial name
- NCT00420641
- Testing
- GSK372475, Paroxetine
- Where
- 33 sites in Bulgaria, Canada and 8 more
- Volunteers
- 492 people
- Sponsor
- GlaxoSmithKline
Bipolar Depression
Bipolar Depression Before and After Lamotrigine Treatment
This study compared glutamate and other neurometabolites measured by proton magnetic resonance spectroscopy (1H-MRS) in bipolar I and II patients currently depressed with age-matched healthy controls.
- Trial name
- 1HMRS-BP (NCT01042496)
- Testing
- Lamotrigine, 1H-MR
- Where
- United States
- Volunteers
- 72 people, healthy volunteers welcome
- Sponsor
- Mayo Clinic
Depressive Disorder, Major Depressive Disorder
Study Evaluating Desvenlafaxine Succinate Sustained-Release Tablets (DVS SR) In The Treatment Of Child and Adolescent Outpatients With Major Depressive Disorder
The primary purpose of this study is to evaluate the long-term safety and tolerability of Desvenlafaxine Succinate Sustained-Release (DVS SR) in child and adolescent outpatients with major depressive disorder.
- Trial name
- NCT00669110
- Testing
- Desvenlafaxine Succinate Sustained-Release Tablets (DVS SR)
- Where
- 9 sites in United States
- Volunteers
- 40 people
- Sponsor
- Wyeth is now a wholly owned subsidiary of Pfizer
Bipolar Depression, Treatment Resistant Depression
Intensive TMS for Bipolar Depression
The research study is being conducted to test whether using high dose spaced theta-burst rTMS (a form of transcranial magnetic stimulation) produces a significant reduction in depressive symptoms compared with sham.
- Trial name
- NCT05228457
- Testing
- Intensive intermittent theta-burst stimulation (iTBS)
- Where
- United States
- Volunteers
- 34 people
- Sponsor
- University of Pennsylvania
Parkinson's Disease
A Study of Tolerability and Efficacy of Cannabidiol on Tremor in Parkinson's Disease
The major purpose of the Stage 1 is to study the safety and tolerability of the proposed dosage regimen of the study drug. The form of cannabidiol (CBD) used in this study is GWP42003, supplied by GW Pharmaceuticals.
- Trial name
- NCT02818777
- Testing
- cannabidiol
- Where
- United States
- Volunteers
- 13 people
- Sponsor
- University of Colorado, Denver
Major Depressive Disorder
Augmenting Single-session Behavioral Activation (BA) With Delta-beta Transcranial Alternating Current Stimulation (tACS) for the Treatment of Depression
Investigating whether delta-beta cross-frequency transcranial alternating current stimulation can augment the effects of a single session of behavioral activation in participants with major depressive disorder.
- Trial name
- ABBA (NCT05693922)
- Testing
- Delta-beta cross-frequency transcranial alternating current stimulation via the NeuroConn DC-STIMULATOR MC, Single-session behavioral activation
- Where
- United States
- Volunteers
- 30 people
- Sponsor
- University of North Carolina, Chapel Hill
Driving Performance, Cognitive Impairment
The Effects of Cannabidiol on the Driving Ability of Healthy Adults
A randomized, parallel-group, double-blind, exploratory two-arm trial to assess the effects of CBD on driving ability along with changes in psychological status (i.e. mood, drowsiness, sedation) and cognitive function.
- Conditions
- Driving Performance, Cognitive Impairment, Sedation Complication, Mood
- Trial name
- NCT04590495
- Testing
- 300 mg Cannabidiol (CBD) oil
- Where
- United States
- Volunteers
- 40 people, healthy volunteers welcome
- Sponsor
- West Virginia University
Major Depressive Disorder, Major Depressive Episode
Universal vs. Targeted School Screening for Adolescent Major Depressive Disorder
The primary goal of the proposed study is to compare the effectiveness of universal school based screening for adolescent major depressive disorder to the current school process of targeted screening based on concerning behavior.
- Trial name
- NCT03716869
- Testing
- Universal Screening Arm
- Where
- United States
- Volunteers
- 12,909 people
- Sponsor
- Milton S. Hershey Medical Center
Depressive Disorder, Major, Depressive Disorder, Treatment-Resistant
Inhaled Nitrous Oxide for Treatment-Resistant Depression: Optimizing Dosing Strategies
The purpose of the study aims to determine whether different concentrations of nitrous oxide (N2O) have different antidepressant effects for adults with treatment-resistant major depression.
- Trial name
- NARSAD (NCT03283670)
- Testing
- Nitrous Oxide 25%, Nitrous Oxide 50%
- Where
- United States
- Volunteers
- 24 people
- Sponsor
- Washington University School of Medicine
Bipolar Disorder
Naturalistic Study, Comparison of Divalproex Extended Release (ER) and Quetiapine for Adults With Acute Mania or Mixed Episodes
The primary objective of this study is to compare the efficacy and tolerability of quetiapine versus divalproex extended-release administered in a rapid oral loading fashion in the treatment of acute episodes of mania or mixed…
- Trial name
- NCT00397020
- Testing
- divalproex ER, quetiapine
- Where
- United States
- Volunteers
- 30 people
- Sponsor
- University of California, San Diego
Stress Disorders, Post-Traumatic, PTSD
Ketamine as a Rapid Treatment for Post-traumatic Stress Disorder (PTSD)
The objective of the proposed study is to test if a single IV dose of ketamine (0.5 mg/kg) decreases symptoms of PTSD.
- Conditions
- Stress Disorders, Post-Traumatic, PTSD, Depression, Anxiety Disorder
- Trial name
- KetPTSD (NCT00749203)
- Testing
- Midazolam, Ketamine
- Where
- United States
- Volunteers
- 41 people
- Sponsor
- Dennis Charney
Bipolar Disorder
Repetitive Transcranial Magnetic Stimulation (rTMS) for Treatment Resistant Bipolar Depression
We hope to learn whether this stimulation of neurons in the front part of the brain may relieve depression.
- Trial name
- NCT00186485
- Testing
- MagStim
- Where
- United States
- Volunteers
- 28 people
- Sponsor
- Stanford University
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.